+Compare
PTCT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.71B

PTCT PTC Therapeutics Forecast, Technical & Fundamental Analysis

a developer of biopharmaceutical products

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for PTCT with price predictions
08:00 PM EDT Sep 28, 2023

Momentum Indicator for PTCT turns negative, indicating new downward trend

PTCT saw its Momentum Indicator move below the 0 level on September 13, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned negative. In of the 97 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for PTCT turned negative on September 13, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .

PTCT moved below its 50-day moving average on September 13, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PTCT crossed bearishly below the 50-day moving average on September 14, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PTCT entered a downward trend on September 20, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PTCT advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

PTCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PTCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PTCT's P/B Ratio (1666.667) is very high in comparison to the industry average of (22.693). P/E Ratio (0.000) is within average values for comparable stocks, (131.605). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.099). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (2.026) is also within normal values, averaging (304.777).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 402 to 410.54B. NVO holds the highest valuation in this group at 410.54B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 23%, and the average quarterly price growth was 42%. CRIS experienced the highest price growth at 1,363%, while BCLI experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was 41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

PTCT is expected to report earnings to fall 57.52% to -112 cents per share on October 26

PTC Therapeutics PTCT Stock Earnings Reports
Q3'23
Est.
$-1.13
Q2'23
Missed
by $1.08
Q1'23
Missed
by $0.40
Q4'22
Missed
by $0.78
Q3'22
Missed
by $0.22
The last earnings report on August 03 showed earnings per share of -266 cents, missing the estimate of -158 cents. With 638.12K shares outstanding, the current market capitalization sits at 1.71B.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
100 Corporate Court
Phone
+1 908 222-7000
Employees
1410
Web
https://www.ptcbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PGTRX47.180.12
+0.25%
Putnam Global Technology R
FICEX14.95N/A
N/A
Frost Growth Equity Inst
CSPEX55.20-0.05
-0.09%
American Funds SMALLCAP World 529E
DUSLX28.10-0.08
-0.28%
DFA US Large Cap Growth Instl
SUPCX13.72-0.06
-0.44%
DWS Equity Sector Strategy Fund Class C

PTCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTCT has been loosely correlated with CYTK. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PTCT jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
-1.10%
CYTK - PTCT
51%
Loosely correlated
-4.35%
OCGN - PTCT
41%
Loosely correlated
+1.23%
SRPT - PTCT
36%
Loosely correlated
-1.92%
AGIO - PTCT
36%
Loosely correlated
-0.12%
FGEN - PTCT
36%
Loosely correlated
-11.18%
More

Groups containing PTCT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTCT
1D Price
Change %
PTCT100%
-1.10%
biopharmaceuticals
(undefined stocks)
42%
Loosely correlated
-0.46%
drugs
(undefined stocks)
32%
Poorly correlated
+5.05%
biotechnology
(undefined stocks)
32%
Poorly correlated
+5.41%